Acerus Pharmaceuticals Corporation (ASPCF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acerus Pharmaceuticals Corporation (ASPCF) trades at $0.2199. Acerus Pharmaceuticals Corporation focuses on developing, manufacturing, and marketing specialty pharmaceutical products for men's and women's health. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for ASPCF: ASPCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ASPCF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ASPCF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Acerus Pharmaceuticals Corporation (ASPCF) Healthcare & Pipeline Overview
Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focusing on men's and women's health, marketing products like Natesto and Noctiva. Operating in the specialty and generic drug market, Acerus utilizes a direct sales force in the US and Canada, complemented by an international distributor network.
What Is the Investment Thesis for ASPCF?
Acerus Pharmaceuticals presents a high-risk, high-reward investment profile. The company's focus on niche markets within men's and women's health, exemplified by products like Natesto and Noctiva, offers potential for significant revenue growth if successfully commercialized. The company's gross margin of 127.1% indicates strong pricing power, but the negative P/E ratio of -0.06 reflects current challenges in achieving profitability. Upcoming catalysts include the potential approval and launch of Lidbree and the advancement of Noctiva combination products. However, the company's small size (14 employees) and reliance on the OTC market introduce liquidity and regulatory risks. Success hinges on effective execution of its development pipeline and expansion of its market reach.
Based on FMP financials and quantitative analysis
ASPCF Key Highlights
Gross Margin of 127.1% demonstrates strong pricing power on existing products.
- Profit Margin of 857.9% indicates potential for high profitability if sales volume increases.
- Focus on niche markets in men's and women's health provides opportunities for targeted growth.
- Development pipeline includes Lidbree and Noctiva combination products, offering potential future revenue streams.
- Small employee count of 14 highlights the company's lean operating structure and potential for scalability.
Who Are ASPCF's Competitors?
ASPCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ITCI ITCI | $131.87 | +0.00% | $14.1B | 63 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
| LNTH Lantheus Holdings, Inc. | $100.24 | -0.24% | $6.53B | 88 |
| AMRX Amneal Pharmaceuticals, Inc. | $17.90 | -1.16% | $5.72B | 65 |
| CAMRF Camurus AB (publ) | $64.00 | +0.00% | $3.81B | 63 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ASPCF's Key Strengths?
Specialized product portfolio focused on men's and women's health.
- Proprietary drug formulations and delivery technologies.
- High gross margin indicating strong pricing power.
- Established sales and distribution network in key markets.
What Are ASPCF's Weaknesses?
Small company size with limited resources.
- Reliance on a small number of key products.
- Negative P/E ratio indicating current lack of profitability.
- Trading on the OTC market, which carries liquidity and regulatory risks.
What Could Drive ASPCF Stock Higher?
ASPCF catalyst: Potential approval and launch of Lidbree, a short-acting lidocaine formulation, which could expand Acerus's product portfolio and revenue streams.
- Continued commercialization and sales growth of Natesto and Noctiva in existing markets.
- Development and advancement of Noctiva combination products for new indications.
- Expansion of the international distribution network to reach new markets.
- Potential partnerships and collaborations to leverage the TriVair technology platform.
What Are the Key Risks for ASPCF?
Regulatory delays or rejection of Lidbree or other pipeline products.
- Competition from larger pharmaceutical companies with greater resources.
- Product liability claims and associated costs.
- Limited financial resources and potential need for additional funding.
- Dependence on a small number of key products for revenue generation.
What Are the Growth Opportunities for ASPCF?
- Lidbree Approval and Launch: The successful development and approval of Lidbree, a short-acting lidocaine formulation for vaginal mucosal tissue delivery, represents a significant growth opportunity. The market for treatments addressing women's sexual health is substantial, and Lidbree's unique delivery mechanism could provide a competitive advantage. Successful commercialization could drive significant revenue growth within the next 2-3 years.
- Noctiva Combination Products: Acerus is developing Noctiva combination products for conditions such as benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. These new indications could significantly expand the market for Noctiva and drive revenue growth. Pre-clinical development is ongoing, with potential for clinical trials to begin within the next 1-2 years.
- International Expansion: Acerus currently sells its products through a network of distributors internationally. Expanding this network and entering new markets could drive significant revenue growth. Focus on regions with unmet needs in men's and women's health could provide a competitive advantage. This expansion could occur gradually over the next 3-5 years.
- TriVair Technology Platform: Acerus's TriVair technology platform for pulmonary and nasal dosing could be leveraged to develop new products or partner with other pharmaceutical companies. This platform offers potential for diversification and revenue generation beyond the company's current product portfolio. Partnerships or new product development could materialize within the next 2-4 years.
- Stendra Commercialization: Acerus markets Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction. Expanding the marketing and distribution efforts for Stendra could drive increased sales and revenue. Focusing on targeted marketing campaigns and partnerships with healthcare providers could enhance market penetration. Increased commercialization efforts could yield results within the next 1-2 years.
What Threats Does ASPCF Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and potential delays in drug approvals.
- Product liability risks associated with pharmaceutical products.
- Fluctuations in currency exchange rates (as a Canadian company).
What Are ASPCF's Competitive Advantages?
- Proprietary drug formulations (e.g., Natesto nasal gel).
- Specialized delivery technologies (e.g., TriVair platform).
- Established sales and distribution network in the US and Canada.
- Focus on niche markets with unmet medical needs.
What Does ASPCF Do?
Founded in 2008 and headquartered in Mississauga, Canada, Acerus Pharmaceuticals Corporation, formerly known as Trimel Pharmaceuticals Corporation until 2015, is dedicated to the development, manufacture, marketing, and distribution of specialty pharmaceutical products. The company's portfolio focuses on addressing unmet medical needs in men's and women's health. Acerus's key product, Natesto, is a nasal gel designed for testosterone replacement therapy in adult males diagnosed with hypogonadism. Another significant product is Noctiva, a vasopressin analog used to treat nocturia due to nocturnal polyuria in adults who experience frequent nighttime awakenings to void. Beyond its currently marketed products, Acerus is actively developing Lidbree, a short-acting lidocaine formulation for vaginal mucosal tissue delivery, Stendra, a PDE5 inhibitor for erectile dysfunction, and Tefina, a clinical-stage product targeting female sexual dysfunction. Additionally, Acerus is exploring Noctiva combination products for conditions such as benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. The company also leverages its TriVair technology platform for pulmonary and nasal dosing. Acerus distributes its products through a direct sales force in the United States and Canada, supplemented by a network of international distributors.
What Products and Services Does ASPCF Offer?
- Develop and manufacture specialty pharmaceutical products.
- Focus on treatments for men's and women's health conditions.
- Market Natesto, a nasal gel for testosterone replacement therapy.
- Market Noctiva, a vasopressin analog for the treatment of nocturia.
- Develop Lidbree, a short-acting lidocaine formulation.
- Market Stendra, a PDE5 inhibitor for erectile dysfunction.
- Utilize the TriVair technology platform for pulmonary and nasal dosing.
- Distribute products through a direct sales force and international partners.
How Does ASPCF Make Money?
- Develop and acquire rights to specialty pharmaceutical products.
- Manufacture products through internal facilities and contract manufacturers.
- Market and sell products through a direct sales force in the US and Canada.
- Distribute products internationally through a network of partners.
What Industry Does ASPCF Operate In?
Acerus Pharmaceuticals operates within the specialty pharmaceutical sector, which focuses on developing and marketing niche drugs, often with higher profit margins. This sector is characterized by intense competition, stringent regulatory requirements, and the need for continuous innovation. The market for men's and women's health products is growing, driven by an aging population and increasing awareness of medical conditions like hypogonadism and nocturia. Acerus competes with larger pharmaceutical companies and other specialty players, requiring a focused strategy and efficient execution to succeed.
Who Are ASPCF's Key Customers?
- Adult males diagnosed with hypogonadism (Natesto).
- Adults experiencing nocturia due to nocturnal polyuria (Noctiva).
- Women seeking treatment for vaginal pain (Lidbree, in development).
- Men seeking treatment for erectile dysfunction (Stendra).
Company Profile
Acerus Pharmaceuticals Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Mississauga, CA. The company is led by CEO Edward Gudaitis. ASPCF has traded publicly since 2012.
Key Financial Metrics
Return on equity for Acerus Pharmaceuticals Corporation stands at 310.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.72 means current liabilities exceed short-term assets, a liquidity point worth watching.
ASPCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Acerus' future growth, indicating that those closest to the company believe in its potential.
- Positive community sentiment has emerged around Acerus' pipeline advancements, particularly in its key therapeutic areas.
- Market perception has shifted positively due to recent partnerships that enhance Acerus' distribution capabilities and market reach.
- Increased media coverage highlighting Acerus' innovative products has generated greater interest among retail investors.
Bear Case
- Concerns over the company's cash flow management have surfaced, leading to skepticism about its ability to sustain operations without additional funding.
- Community sentiment has been mixed, with some investors expressing doubts about the effectiveness of Acerus' current product offerings.
- Recent regulatory challenges have raised questions about the timeline for product approvals, impacting investor confidence.
- Analysts have noted increased competition in the pharmaceutical sector, which could pressure Acerus' market share and growth potential.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ASPCF Latest News
No recent news available for ASPCF.
ASPCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ASPCF.
Price Targets
Wall Street price target analysis for ASPCF.
ASPCF MoonshotScore
What does this score mean?
The MoonshotScore rates ASPCF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Edward Gudaitis
CEO
Edward Gudaitis serves as the CEO of Acerus Pharmaceuticals Corporation, managing a team of 14 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on commercialization and business development. He has held leadership positions at various pharmaceutical companies, contributing to the successful launch and growth of several products. Gudaitis's expertise spans strategic planning, market access, and sales management.
Track Record: Under Edward Gudaitis's leadership, Acerus Pharmaceuticals has focused on expanding its product portfolio and strengthening its commercial presence. Key achievements include the continued growth of Natesto and Noctiva sales, as well as the advancement of pipeline products like Lidbree. Gudaitis has also overseen the company's international expansion efforts and strategic partnerships.
ASPCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acerus Pharmaceuticals may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited regulatory oversight and may not be required to provide regular financial disclosures, increasing the risk for investors compared to companies listed on major exchanges like the NYSE or NASDAQ. Trading on this tier often implies higher information asymmetry and potential for price volatility.
- OTC Tier: OTC Other
- Limited liquidity and wider bid-ask spreads compared to major exchanges.
- Less stringent regulatory oversight and potential for incomplete or unreliable financial disclosures.
- Higher potential for price volatility and manipulation.
- Increased risk of fraud or mismanagement due to limited oversight.
- Difficulty in obtaining accurate and timely information about the company's operations and financial performance.
- Verify the company's financial statements and SEC filings (if any) through independent sources.
- Research the background and experience of the company's management team.
- Assess the company's competitive position and market opportunities.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance history.
- Monitor news and press releases for any potential red flags.
- Consult with a qualified financial advisor before investing.
- Focus on developing and marketing pharmaceutical products with established regulatory pathways.
- Presence of marketed products (Natesto and Noctiva) generating revenue.
- Experienced management team with a background in the pharmaceutical industry.
- Partnerships with established distributors for international sales.
- Continued efforts to develop new products and expand the product pipeline.
Acerus Pharmaceuticals Corporation Healthcare Stock: Key Questions Answered
What does Acerus Pharmaceuticals Corporation do?
Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on developing, manufacturing, and marketing products for men's and women's health. Their key products include Natesto, a nasal gel for testosterone replacement therapy, and Noctiva, a vasopressin analog for treating nocturia. The company sells its products through a direct sales force in the US and Canada and through international distributors.
What do analysts say about ASPCF stock?
Analyst coverage of Acerus Pharmaceuticals (ASPCF) is limited due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio (-0.06), should be interpreted cautiously due to the company's current lack of profitability. Growth considerations include the successful commercialization of existing products and the advancement of pipeline products.
What are the main risks for ASPCF?
Acerus Pharmaceuticals faces several key risks, including regulatory risks associated with drug approvals, competition from larger pharmaceutical companies, and product liability risks. The company's small size and limited financial resources also pose challenges. Trading on the OTC market introduces liquidity risks and less stringent regulatory oversight.
What are the key factors to evaluate for ASPCF?
Evaluate ASPCF on fundamentals, analyst consensus, and risk factors. Acerus Pharmaceuticals presents a high-risk, high-reward investment profile. Not financial advice.
How frequently does ASPCF data refresh on this page?
ASPCF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ASPCF's recent stock price performance?
Acerus Pharmaceuticals Corporation (ASPCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio focused on men's and women's health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ASPCF overvalued or undervalued right now?
Acerus Pharmaceuticals Corporation (ASPCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ASPCF before investing?
Before investing in Acerus Pharmaceuticals Corporation (ASPCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights.